Search results
2 gru 2019 · Base-case analysis showed aspirin therapy was more costly (USD1,086 versus USD819) with higher QALYs gained (11.94 versus 11.86 QALYs) compared to no use of aspirin. The base-case results were sensitive to the odds ratio of all-cause death in aspirin therapy versus no use of aspirin.
6 cze 2002 · Results. The extension of aspirin therapy from the current levels of use to all eligible patients for 25 years would have an estimated cost-effectiveness ratio of about $11,000 per...
1 sie 2021 · The term “economy class syndrome” refers to the occurrence of thrombotic events that mainly occur in passengers in the economy class of the aircraft during long-haul flights.
27 maj 2008 · However, women 65 years of age with a 5-times-increased cardiovascular risk aspirin tended to have favorable health outcomes against higher costs compared with no treatment. The incremental cost-utility ratio of aspirin treatment compared with no treatment was 5747 euros per QALY gained.
lower risk of bleeding and hospitalization compared with triple therapy (VKA dose adjusted to an interna-tional normalized ratio [INR] of 2–3, aspirin, clopido-grel). The magnitude of difference in bleeding events was dose dependent (HR, 0.52; 95% CI, 0.42–0.63; and HR, 0.72; 95% CI, 0.58–0.88 for the dabigatran
5 cze 2014 · Compared with aspirin alone, clopidogrel‐aspirin resulted in a lifetime gain of 0.037 QALYs at an additional cost of CNY 1250 (US$ 192), yielding an incremental cost‐effectiveness ratio of CNY 33 800 (US$ 5200) per QALY gained.
1 sie 2014 · The economic benefit of tirofiban plus heparin and aspirin versus standard treatment with heparin plus aspirin in patients with acute coronary ischaemic syndromes was evaluated in the study of Szucs et al. performed in Switzerland, based on efficacy data from the PRISM-PLUS (Platelet Receptor Inhibition in Ischemic Syndrome Management in ...
